This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dressman, H. K. Articles by Lancaster, J. M. Search for Related Content PubMed PubMed Citation Articles by Dressman, H. K. Articles by Lancaster, J. M. Related Articles Related Correspondence Social Bookmarking                            What's this?

An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer

Holly K. Dressman, Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, Jennifer Clarke, Regina S. Whitaker, LiHua Li, Jonathan Gray, Jeffrey Marks, Geoffrey S. Ginsburg, Anil Potti, Mike West, Joseph R. Nevins, Johnathan M. Lancaster

From the Divisions of Gynecologic Surgical Oncology and Cancer Prevention and Control, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Institute for Genome Sciences and Policy, Department of Molecular Genetics and Microbiology, Department of Obstetrics and Gynecology/Division of Gynecologic Oncology, and Departments of Surgery and Medicine, Duke University Medical Center; Institute of Statistics and Decision Sciences, Duke University, Durham, NC; and Institute of Medical Genetics, University Hospital of Wales, Cardiff, United Kingdom

Address reprint requests to Johnathan M. Lancaster, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612; e-mail: lancasjm{at}moffitt.usf.edu

Purpose The purpose of this study was to develop an integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease.

Patients and Methods A gene expression model that predicts response to platinum-based therapy was developed using a training set of 83 advanced-stage serous ovarian cancers and tested on a 36-sample external validation set. In parallel, expression signatures that define the status of oncogenic signaling pathways were evaluated in 119 primary ovarian cancers and 12 ovarian cancer cell lines. In an effort to increase chemotherapy sensitivity, pathways shown to be activated in platinum-resistant cancers were subject to targeted therapy in ovarian cancer cell lines.

Results Gene expression profiles identified patients with ovarian cancer likely to be resistant to primary platinum-based chemotherapy with greater than 80% accuracy. In patients with platinum-resistant disease, we identified expression signatures consistent with activation of Src and Rb/E2F pathways, components of which were successfully targeted to increase response in ovarian cancer cell lines.

Conclusion We have defined a strategy for treatment of patients with advanced-stage ovarian cancer that uses therapeutic stratification based on predictions of response to chemotherapy, coupled with prediction of oncogenic pathway deregulation, as a method to direct the use of targeted agents.

Supported by the Ovarian Cancer Research Fund, Gynecologic Cancer Foundation's Molly Cade Ovarian Cancer Award, Hearing the Ovarian Cancer Whisper Organization, and the Jacquie Liggett Fellowship in Ovarian Cancer Research.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Run Batch Effects Potentially Compromise the Usefulness of Genomic Signatures for Ovarian Cancer
  Keith A. Baggerly, Kevin R. Coombes, and E. Shannon Neeley
  JCO 2008 26: 1186-1187 [Full Text]

This article has been cited by other articles:

				E. Vilar, B. Mukherjee, R. Kuick, L. Raskin, D. E. Misek, J. M.G. Taylor, T. J. Giordano, S. M. Hanash, E. R. Fearon, G. Rennert, et al. Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway Clin. Cancer Res., April 15, 2009; 15(8): 2829 - 2839. [Abstract] [Full Text] [PDF]

				N. Eckstein, K. Servan, B. Hildebrandt, A. Politz, G. v. Jonquieres, S. Wolf-Kummeth, I. Napierski, A. Hamacher, M. U. Kassack, J. Budczies, et al. Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells Cancer Res., April 1, 2009; 69(7): 2996 - 3003. [Abstract] [Full Text] [PDF]

				J. B. Overdevest, D. Theodorescu, and J. K. Lee Utilizing the Molecular Gateway: The Path to Personalized Cancer Management Clin. Chem., April 1, 2009; 55(4): 684 - 697. [Abstract] [Full Text] [PDF]

				A. Berchuck, E. S. Iversen, J. Luo, J. P. Clarke, H. Horne, D. A. Levine, J. Boyd, M. A. Alonso, A. A. Secord, M. Q. Bernardini, et al. Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome Clin. Cancer Res., April 1, 2009; 15(7): 2448 - 2455. [Abstract] [Full Text] [PDF]

				A. H. Beck, I. Espinosa, B. Edris, R. Li, K. Montgomery, S. Zhu, S. Varma, R. J. Marinelli, M. van de Rijn, and R. B. West The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma Clin. Cancer Res., February 1, 2009; 15(3): 778 - 787. [Abstract] [Full Text] [PDF]

				J. A. Ajani, J. G. Izzo, and J.-S. Lee Chemotherapy and Radiotherapy Resistance: Complexity, Reality, and Promise J. Clin. Oncol., January 1, 2009; 27(1): 162 - 163. [Full Text] [PDF]

				R. W. Tothill, A. V. Tinker, J. George, R. Brown, S. B. Fox, S. Lade, D. S. Johnson, M. K. Trivett, D. Etemadmoghadam, B. Locandro, et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome Clin. Cancer Res., August 15, 2008; 14(16): 5198 - 5208. [Abstract] [Full Text] [PDF]

				B. Singh and D. G. Pfister Individualized Treatment Selection in Patients With Head and Neck Cancer: Do Molecular Markers Meet the Challenge? J. Clin. Oncol., July 1, 2008; 26(19): 3114 - 3116. [Full Text] [PDF]

				S. B. Kaye Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here? J. Clin. Oncol., June 1, 2008; 26(16): 2616 - 2618. [Full Text] [PDF]

				J. C. Mansour and D. G. Coit Appropriate Treatment for Patients with Gastric Adenocarcinoma Ann. Surg. Oncol., June 1, 2008; 15(6): 1798 - 1799. [Full Text] [PDF]

				K. A. Baggerly, K. R. Coombes, and E. S. Neeley Run Batch Effects Potentially Compromise the Usefulness of Genomic Signatures for Ovarian Cancer J. Clin. Oncol., March 1, 2008; 26(7): 1186 - 1187. [Full Text] [PDF]

				T. A. D'Amico Molecular Biologic Staging of Lung Cancer Ann. Thorac. Surg., February 1, 2008; 85(2): S737 - S742. [Abstract] [Full Text] [PDF]

				K. S. Garman, J. R. Nevins, and A. Potti Genomic strategies for personalized cancer therapy Hum. Mol. Genet., October 15, 2007; 16(R2): R226 - R232. [Abstract] [Full Text] [PDF]

				J. D. Minna, L. Girard, and Y. Xie Tumor mRNA Expression Profiles Predict Responses to Chemotherapy J. Clin. Oncol., October 1, 2007; 25(28): 4329 - 4336. [Full Text] [PDF]

				J. K. Lee, D. M. Havaleshko, H. Cho, J. N. Weinstein, E. P. Kaldjian, J. Karpovich, A. Grimshaw, and D. Theodorescu A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery PNAS, August 7, 2007; 104(32): 13086 - 13091. [Abstract] [Full Text] [PDF]

				R. S. N. Fehrmann, X.-y. Li, A. G. J. van der Zee, S. de Jong, G. J. te Meerman, E. G. E. de Vries, and A. P. G. Crijns Profiling Studies in Ovarian Cancer: A Review Oncologist, August 1, 2007; 12(8): 960 - 966. [Abstract] [Full Text] [PDF]